Northwire Canada EditionFriday, September 4, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4539.90 +2.8% SILVER 67.58 +3.2% COPPER 6.67 +1.1% OIL 91.30 +0.3% PALLADIUM 1435.50 +5.5% SALT 1.65 +0.0% BBB 0.670 +3.1% SKE 45.71 +4.0% NOU 1.91 −4.0% LAM 0.660 +6.5% OGW 1.29 −5.2% COCO 0.300 +0.0% CPL 0.195 −11.4% FUU 0.145 −3.3% NUAG 9.25 −0.1% FDY 5.14 −1.9% GRZ 6.66 +0.1% TES 0.110 +10.0% MINK 0.100 +0.0% CAN 0.080 +0.0% ELEF 0.135 −12.9% GOLD 4539.90 +2.8% SILVER 67.58 +3.2% COPPER 6.67 +1.1% OIL 91.30 +0.3% PALLADIUM 1435.50 +5.5% SALT 1.65 +0.0% BBB 0.670 +3.1% SKE 45.71 +4.0% NOU 1.91 −4.0% LAM 0.660 +6.5% OGW 1.29 −5.2% COCO 0.300 +0.0% CPL 0.195 −11.4% FUU 0.145 −3.3% NUAG 9.25 −0.1% FDY 5.14 −1.9% GRZ 6.66 +0.1% TES 0.110 +10.0% MINK 0.100 +0.0% CAN 0.080 +0.0% ELEF 0.135 −12.9%
Regulatory Routine −

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

By The Northwire Desk — AI Analysis Apr 13, 2026 · 16:35 BIOV · 0.05 BioVaxys Technology Corp.
BIOV · Price

Executive Summary

  • BioVaxys is providing a bi-weekly update regarding a Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission (BCSC) on March 3, 2026.
  • The company has failed to file its audited annual financial statements and related certifications for the fiscal year ended October 31, 2025.
  • Management anticipates completing the overdue annual filings by April 28, 2026, which will subsequently delay the filing of interim financial statements.

Key Details

  • Missing Annual Filings: Audited annual financial statements for the year ended October 31, 2025, management’s discussion and analysis (MD&A), and Form 52-109FV1 CEO and CFO certifications (originally due February 28, 2026).
  • Expected Completion Date: April 28, 2026.
  • Auditor: Dale Matheson Carr-Hilton LaBonte LLP.
  • Impact on Interim Filings: The company anticipates it will miss the April 1, 2026, deadline for interim financial statements and MD&A for the three months ended January 31, 2025; these will be filed immediately following the annual filings.
  • MCTO Restrictions:
    • Prohibits the CEO and CFO from trading securities of the Company.
    • Prohibits the Company from directly or indirectly issuing or acquiring securities from insiders or employees until filings are complete and the MCTO is revoked.
  • Public Trading Status: The general investing public can continue to trade the company's listed common shares freely.
  • Compliance Status: The company confirms it is not subject to any insolvency proceedings and is adhering to alternative information guidelines under NP 12-203 by issuing bi-weekly status reports.
Read the original news release →

More from BioVaxys Technology Corp.

May 01, 2026 · 08:01

BioVaxys Preclinical Validation Amidst Compliance Overhang and Liquidity Constraints

Other Apr 28, 2026 · 16:30

BioVaxys Shares Plunge as Filing Default Extends Amidst Clinical Progress

Regulatory Apr 27, 2026 · 08:01

BioVaxys Shares Plunge Amid Compliance Risks Despite ASCO Presentation

Other Mar 10, 2026 · 08:00

BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines

Other Mar 03, 2026 · 16:30

BioVaxys Announces Application for Management Cease Trade Order

Management Jan 29, 2026 · 08:00

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

Other